Title of article
Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
Author/Authors
Erta?، Rag?p نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Erta?, Rag?p , ?zyurt، Kemal نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey ?zyurt, Kemal , Y?ld?z، Sinem نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Y?ld?z, Sinem , Ula?، Y?lmaz نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Ula?, Y?lmaz , Turasan، Abdullah نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Turasan, Abdullah , Avc?، At?l نويسنده Kayseri Education and Research Hospital, Department of Dermatology and Venereology, Kayseri, Turkey Avc?, At?l
Issue Information
دوماهنامه با شماره پیاپی 0 سال 2016
Pages
5
From page
82
To page
86
Abstract
Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.
Journal title
Iranian Journal of Allergy, Asthma and Immunology
Serial Year
2016
Journal title
Iranian Journal of Allergy, Asthma and Immunology
Record number
2387935
Link To Document